ArticleFrontiers in pharmacology2022

Discovery of a potent olaparib-chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer.

Hongyu Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.